HMG-CoA还原酶
重组DNA
促排卵素
促性腺激素
促卵泡激素
医学
内科学
内分泌学
生物
男科
激素
促排卵
促黄体激素
排卵
遗传学
基因
生物化学
还原酶
酶
作者
Giuseppe De Placido,Antonio Mollo,Carlo Alviggi,Ida Strina,Maria Teresa Varricchio,Antonio Ranieri,Nicola Colacurci,Achille Tolino,Martin Wilding
出处
期刊:Human Reproduction
[Oxford University Press]
日期:2001-09-01
卷期号:16 (9): 1875-1879
被引量:96
标识
DOI:10.1093/humrep/16.9.1875
摘要
BACKGROUND: The aim of this study was to investigate the effects of adding human menopausal gonadotrophin (HMG) during controlled ovarian stimulation in normoovulatory normogonadotrophic patients showing an initial suboptimal response to a standardized long protocol therapy with recombinant FSH (rFSH) (300 IU/day). METHODS: A total of 43 such patients were randomized in two groups. In Group A, 150 IU rFSH was substituted by 150 IU HMG after day 8 of stimulation. The stimulation protocol of Group B involved a simple increase of the daily rFSH dose to 375 IU after day 8. A total of 40 BMI and age matched patients with an optimal ovarian response formed the control group (Group C). RESULTS: The mean Group A serum concentration of oestradiol on the day of HCG administration and average number of oocytes retrieved were significantly higher than Group B (P < 0.001) and equivalent to Group C. A total of 10 pregnancies (50%) in Group A, 8 (34.8%) in Group B and 19 (47.5%) in the control group were achieved. CONCLUSIONS: The data suggest that LH supplementation improves the ovarian outcome in patients characterized by an inadequate initial response to rFSH therapy in a long protocol.
科研通智能强力驱动
Strongly Powered by AbleSci AI